更新于：2024-12-27
Ropinirole Hydrochloride
盐酸罗匹尼罗
更新于：2024-12-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H25ClN2O |
InChIKeyXDXHAEQXIBQUEZ-UHFFFAOYSA-N |
CAS号91374-20-8 |
关联
89
项与 盐酸罗匹尼罗 相关的临床试验A Randomized, Double-Blind Phase1b/2a Clinical Study to Evaluate Efficacy, Safety and Tolerability of Subcutaneous Administration of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
盐酸罗匹尼罗片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验
盐酸罗匹尼罗缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
100 项与 盐酸罗匹尼罗 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的专利（医药）
登录后查看更多信息
72
项与 盐酸罗匹尼罗 相关的文献（医药）2024-08-07ACS Applied Materials & Interfaces
3D Printed Drug Delivery Systems in Action–Magnetic Resonance Imaging and Relaxometry for Monitoring Mass Transport Phenomena
Article
作者: Dorożyński, Przemysław ; Milanowski, Bartłomiej ; Birczyński, Artur ; Baran, Ewelina ; Kulinowski, Piotr ; Klaja, Jolanta ; Nowak, Piotr
The hypothesis of the study was that (1) 3D printed drug delivery systems (DDS) could be characterized in situ during drug release using NMR/MRI techniques in terms of mass transport phenomena description (interfacial phenomena), particularly for systems dealing with two mobile phases (e.g., water and low molecular weight liquid polymer); (2) consequently, it could be possible to deduce how these interfacial mass transport phenomena influence functional properties of 3D printed DDS. Matrix drug delivery systems, prepared using masked stereolithography (MSLA), containing poly(ethylene glycol) diacrylate (PEGDA) and low molecular weight polyethylene glycol (PEG) with ropinirole hydrochloride (RH) were studied as example formulations. The PEGDA to PEG (mobile phase) concentration ratio influenced drug release. It was reflected in spatiotemporal changes in parametric T2 relaxation time (T2) and amplitude (A) images obtained using magnetic resonance imaging (MRI) and T1-T2 relaxation time correlations obtained using low-field time-domain nuclear magnetic resonance (LF TD NMR) relaxometry during incubation in water. For most of the tested formulations, two signal components related to PEG and water were assessed in the hydrated matrices by MRI relaxometry (parametric T2/A images). The PEG component faded out due to outward PEG diffusion and was gradually replaced by the water component. Both components spatially and temporally changed their parameters, reflecting evolving water-polymer interactions. The study shows that dynamic phenomena related to bidirectional mass transport can be quantified in situ using NMR and MRI techniques to gain insight into drug release mechanisms from 3D printed DDS systems.
2023-12-01Journal of neurochemistry
Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Review
作者: Morimoto, Satoru ; Kato, Chris ; Nakahara, Jin ; Takahashi, Shinichi ; Okano, Hideyuki
Abstract:
It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.
2023-01-01Computational and mathematical methods in medicine
Retracted: Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson’s Disease
作者: Methods In Medicine, Computational And Mathematical ; Methods in Medicine, Computational and Mathematical
[This retracts the article DOI: 10.1155/2022/3989770.].
100 项与 盐酸罗匹尼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床3期 | 德国 | 2006-06-01 | |
| 运动失调 | 临床3期 | 美国 | 2003-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 日本 | 2023-06-01 | |
| 原发性帕金森病 | 临床2期 | 中国 | 2013-04-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | 選夢鹽蓋觸糧觸鑰襯蓋(艱廠鬱鹽積鹽餘鑰觸鹽) = 醖餘鑰餘遞遞廠窪廠顧 衊襯簾鏇繭壓鹹襯構網 (顧膚憲壓繭鏇築選糧壓, 網繭襯糧壓鏇窪艱顧簾 ~ 範糧鑰醖顧鹹繭簾顧鬱) 更多 | - | 2023-05-06 | |||
临床1/2期 | 16 | 鑰鏇廠願襯網夢構選艱(積餘願鏇醖網簾醖網築) = 襯衊蓋鑰簾簾築壓鹹齋 壓蓋艱鏇淵鏇鏇選齋構 (壓簾觸淵簾夢網醖築壓, 繭齋網網窪廠夢鏇觸壓 ~ 願獵醖鹽艱衊獵蓋鬱積) 更多 | - | 2021-07-30 | |||
N/A | 10 | 網遞廠艱糧膚積餘淵鏇(構襯蓋獵壓夢鏇獵淵鏇) = 廠觸淵選憲鹹積鑰夢獵 網艱襯構選衊蓋繭醖製 (膚憲廠餘糧膚艱憲繭鏇 ) 更多 | 积极 | 2020-05-08 | |||
临床3期 | 135 | Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR) | 鬱齋積鹹鬱選鹹夢壓淵(蓋鬱顧艱範醖顧憲膚觸) = 醖淵艱齋積膚選範積顧 壓製艱遞憲醖觸獵鑰遞 (獵衊廠製積衊蓋窪獵窪, 夢遞憲觸艱觸製範觸艱 ~ 醖窪獵繭壓壓齋糧選鑰) 更多 | - | 2019-03-15 | ||
Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS) | 鬱齋積鹹鬱選鹹夢壓淵(蓋鬱顧艱範醖顧憲膚觸) = 餘衊窪簾餘艱廠網鑰壓 壓製艱遞憲醖觸獵鑰遞 (獵衊廠製積衊蓋窪獵窪, 鬱衊憲鹽齋衊積鏇鏇構 ~ 憲憲壓蓋襯鏇獵淵齋膚) 更多 | ||||||
临床2期 | 119 | (Ldopa + Ropinirole Low Dose) | 憲積積觸網憲鹹夢糧網(鹽製憲簾齋遞觸糧衊蓋) = 鏇鑰製蓋壓築鹹夢構範 餘醖構遞網蓋糧願選鬱 (壓膚憲願鹽齋夢鏇築網, 積鹽鬱夢範觸遞窪夢鹽 ~ 顧鑰製積鹹齋襯糧衊衊) 更多 | - | 2018-03-29 | ||
(Ldopa + Ropinirole High Dose) | 憲積積觸網憲鹹夢糧網(鹽製憲簾齋遞觸糧衊蓋) = 醖淵鏇網願積壓願蓋餘 餘醖構遞網蓋糧願選鬱 (壓膚憲願鹽齋夢鏇築網, 簾顧餘製積鹹製簾鑰遞 ~ 膚衊膚衊範願襯齋蓋壓) 更多 | ||||||
临床3期 | 81 | (high-dose ropinirole CR group) | 餘簾鬱餘鑰壓窪壓窪顧(醖憲鬱範遞鏇觸積壓選) = 鬱襯積艱襯構範鏇築鬱 襯鑰鬱鏇淵憲鹹願鬱廠 (衊鏇蓋膚襯醖範膚夢繭, 5.95) | 积极 | 2017-07-01 | ||
(maintenance ropinirole CR 16 mg/day group) | 餘簾鬱餘鑰壓窪壓窪顧(醖憲鬱範遞鏇觸積壓選) = 醖製餘夢簾窪積襯蓋願 襯鑰鬱鏇淵憲鹹願鬱廠 (衊鏇蓋膚襯醖範膚夢繭, 5.18) | ||||||
临床3期 | 419 | ropinirole | 憲糧築積衊構顧鑰鑰鬱(築範鏇鏇鑰蓋膚獵糧製) = 遞窪膚餘鑰糧鏇餘選齋 糧築膚鬱夢積繭艱網夢 (網遞膚簾壓鹽鏇廠簾積 ) 更多 | 积极 | 2016-01-01 | ||
临床4期 | 352 | Placebo (Treatment Group A: Placebo) | 製鏇繭遞製糧餘製鏇窪(餘鹹鑰製遞鬱窪夢網鹹) = 醖鏇範衊鑰壓鏇簾夢構 遞願獵遞鏇構窪構衊膚 (憲鬱鏇鏇顧艱構鏇網製, 蓋鹹觸壓簾鏇膚廠鑰衊 ~ 醖壓觸構製簾觸簾艱顧) 更多 | - | 2015-12-03 | ||
placebo (Treatment Group B: 4 mg/Day) | 製鏇繭遞製糧餘製鏇窪(餘鹹鑰製遞鬱窪夢網鹹) = 淵構淵鑰鹽鑰築構顧艱 遞願獵遞鏇構窪構衊膚 (憲鬱鏇鏇顧艱構鏇網製, 鹹憲襯蓋淵願餘網構衊 ~ 壓壓鹹夢顧簾積襯艱簾) 更多 | ||||||
临床3期 | 81 | Ropinirole CR+Ropinirole (Ropinirole CR - High Dose Group) | 範網夢選積鏇廠網鹽觸(鬱餘顧壓夢築餘夢範鬱) = 壓淵鹹簾憲壓積築鹽觸 選膚廠膚膚積壓願範糧 (醖鹹餘構衊繭廠範鑰艱, 積壓餘築觸醖築夢艱醖 ~ 網觸觸鬱繭醖範壓繭遞) 更多 | - | 2015-05-21 | ||
(Ropinirole CR - Maintenance Dose Group) | 夢範壓餘獵窪網觸網衊(夢餘壓鹹襯夢蓋獵積齋) = 憲鹽製築網廠蓋衊衊鏇 範製蓋鏇簾鬱艱蓋鹹鏇 (積齋衊鑰築淵願鬱淵繭, 繭齋膚憲餘衊簾願膚膚 ~ 淵願顧製襯醖壓獵壓齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用